EW - Edwards Lifesciences Corporation

NYSE - NYSE Delayed Price. Currency in USD
195.46
+1.45 (+0.75%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close194.01
Open194.17
Bid0.00 x 900
Ask0.00 x 900
Day's Range193.11 - 196.18
52 Week Range134.53 - 197.86
Volume1,141,571
Avg. Volume1,287,331
Market Cap40.622B
Beta (3Y Monthly)0.95
PE Ratio (TTM)54.32
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Edwards Lifesciences Reports Second Quarter Results
    PR Newswire9 hours ago

    Edwards Lifesciences Reports Second Quarter Results

    IRVINE, Calif. , July 23, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...

  • ACCESSWIRE11 hours ago

    Edwards Lifesciences Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 23, 2019 / Edwards Lifesciences Corp. (NYSE: EW ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 23, 2019 at 5:00 PM ...

  • Edwards Comments On Updated TAVR National Coverage Determination
    PR Newswirelast month

    Edwards Comments On Updated TAVR National Coverage Determination

    "We commend CMS on its thoughtful approach toward updating the TAVR policy. Throughout the NCD process, Edwards emphasized that the priority must be ensuring timely patient access to high-quality care, so that clinicians can provide all people with heart valve disease with the therapy that is right for them.

  • Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
    PR Newswire2 months ago

    Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

    IRVINE, Calif. , June 4, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation
    PR Newswire2 months ago

    Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation

    IRVINE, Calif., June 3, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received notice of an unsolicited "mini-tender offer" by TRC Capital Corporation to purchase up to 1,000,000 shares, or approximately 0.48 percent of the company's outstanding shares of common stock as of the date of the offer. Edwards does not endorse this unsolicited offer and recommends that the company's stockholders reject the offer, either by doing nothing in response or by withdrawing their shares from the offer, if they have responded. Edwards is not affiliated or associated in any way with TRC Capital, its mini-tender offer or the offer documentation.

  • Edwards Announces Milestones For Transcatheter Mitral Program
    PR Newswire2 months ago

    Edwards Announces Milestones For Transcatheter Mitral Program

    Today at the EuroPCR annual course in Paris, new 6-month data from the CLASP study of the PASCAL system were presented by Konstantinos Spargias, M.D., from the Hygeia Hospital in Athens, Greece.  Patients enrolled in the CLASP study had clinically significant mitral regurgitation (MR) despite optimal medical therapy.  The results from treatment with the PASCAL system demonstrated sustained positive outcomes at six months, including 81 percent of patients with mild (1+) or none/trace MR and 98 percent with 2+ MR, with echo core lab adjudication.  Patients experienced clinically and statistically significant improvements in functional status, exercise capability and quality of life sustained at six months.

  • Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020
    PR Newswire2 months ago

    Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020

    IRVINE, Calif., May 15, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the Every Heartbeat Matters signature charitable initiative is on schedule to meet its goal of impacting the global burden of heart valve disease. The initiative, which involves the education, screening and treatment of 1.5 million underserved people by 2020, is supported by grants from Edwards Lifesciences Foundation, donations of Edwards heart valve technologies, volunteer support and the dedicated work of 60 non-profit partners. "Since the Every Heartbeat Matters initiative began five years ago, we have made substantial progress in building a global community that is addressing the burden of heart valve disease for underserved people," said Amanda Fowler, executive director, Edwards Lifesciences Foundation.

  • Favorable Study Outcomes Presented On Edwards Aortic Valves With RESILIA Tissue
    PR Newswire3 months ago

    Favorable Study Outcomes Presented On Edwards Aortic Valves With RESILIA Tissue

    TORONTO, May 7, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced results from the COMMENCE clinical study. The data show that Edwards' bioprosthetic surgical aortic valves featuring the company's novel RESILIA tissue platform continued to demonstrate favorable safety and hemodynamic performance through a median of four years follow-up, with no events of structural valve deterioration (SVD). The COMMENCE study enrolled 694 patients, 144 (21 percent) of which were under the age of 60 when they had surgical valve replacement.

  • Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
    PR Newswire3 months ago

    Edwards Lifesciences To Webcast Annual Meeting Of Stockholders

    IRVINE, Calif. , May 1, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will ...

  • Edwards Lifesciences Reports First Quarter Results
    PR Newswire3 months ago

    Edwards Lifesciences Reports First Quarter Results

    IRVINE, Calif. , April 23, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...

  • Edwards Lifesciences Completes Acquisition of CASMED
    PR Newswire3 months ago

    Edwards Lifesciences Completes Acquisition of CASMED

    IRVINE, Calif., April 18, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the completion of its acquisition of CAS Medical Systems, Inc. (CASM) (CASMED), a medical technology company dedicated to non-invasive brain and tissue oxygenation monitoring. Edwards announced in February that it had signed an agreement to acquire CASMED. Under the terms of the agreement, Edwards paid $2.45 in cash for each common share of CASMED, which equates to an equity value of approximately $100 million.

  • Edwards Lifesciences To Host Earnings Conference Call On April 23, 2019
    PR Newswire3 months ago

    Edwards Lifesciences To Host Earnings Conference Call On April 23, 2019

    IRVINE, Calif. , April 9, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...

  • Edwards SAPIEN 3 Valve Proves Superior To Surgery In Partner 3 Trial
    PR Newswire4 months ago

    Edwards SAPIEN 3 Valve Proves Superior To Surgery In Partner 3 Trial

    The trial, which compared treatment with the SAPIEN 3 valve to surgery in patients with severe symptomatic aortic stenosis (AS) at low risk of death from surgery, achieved superiority of its primary endpoint at one year. The results of the trial will be presented on Sunday as part of the late-breaking clinical trials at the American College of Cardiology's 68th Annual Scientific Session (ACC.19) in New Orleans, and have been published online in the New England Journal of Medicine.

  • Edwards Lifesciences Announces Strategic Investments
    PR Newswire4 months ago

    Edwards Lifesciences Announces Strategic Investments

    IRVINE, Calif., March 11, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two strategic transactions involving companies with structural heart disease technologies. Edwards has invested $35 million in an exclusive right to acquire Corvia Medical, Inc., the developer of the world's first transcatheter device designed to treat heart failure with preserved or mid-range ejection fraction.

  • GlobeNewswire5 months ago

    Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Edwards PASCAL Transcatheter System Receives CE Mark
    PR Newswire5 months ago

    Edwards PASCAL Transcatheter System Receives CE Mark

    IRVINE, Calif., Feb. 19, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the Edwards PASCAL transcatheter valve repair system has received CE Mark for the treatment of patients with mitral regurgitation. "Mitral valve disease is complex, varied and prevalent, and patients are in significant need of multiple safe and effective therapies to treat debilitating symptoms that can lead to a high rate of mortality," said Bernard J. Zovighian, Edwards' corporate vice president, transcatheter mitral and tricuspid therapies. The PASCAL system is designed for effective reduction of mitral regurgitation while respecting the native anatomy.

  • CAS MEDICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CAS Medical Systems, Inc. - CASM
    PR Newswire5 months ago

    CAS MEDICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CAS Medical Systems, Inc. - CASM

    NEW ORLEANS , Feb. 15, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale ...

  • GlobeNewswire5 months ago

    Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of CAS Medical Systems, Inc. (CASM) on Behalf of Stockholders and Encourages CASM Investors to Contact the Firm

    NEW YORK, Feb. 12, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of CAS Medical Systems, Inc. (NASDAQ: CASM) on.

  • PR Newswire5 months ago

    ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of CAS Medical Systems, Inc.

    NEW YORK , Feb. 12, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against CAS Medical Systems, Inc. (NASDAQ: CASM) and its board of directors for breach of fiduciary duty concerning ...

  • GlobeNewswire5 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of CAS Medical Systems, Inc. to Edwards Lifesciences Corporation is Fair to Shareholders

    NEW YORK, Feb. 12, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased CAS Medical Systems, Inc. (“CASMED”.

  • Edwards Lifesciences Enters Into Agreement To Acquire CASMED
    PR Newswire5 months ago

    Edwards Lifesciences Enters Into Agreement To Acquire CASMED

    IRVINE, Calif. and BRANFORD, Conn., Feb. 12, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has entered into a definitive merger agreement to acquire CAS Medical Systems, Inc. (CASM) (CASMED), a medical technology company dedicated to non-invasive monitoring of tissue oxygenation in the brain. "Cerebral oximetry technology provides an important indicator of oxygen levels in the brain, which can enhance clinician decision-making," said Katie Szyman, Edwards' corporate vice president, critical care.

  • GlobeNewswire6 months ago

    Detailed Research: Economic Perspectives on Edwards Lifesciences, Zimmer Biomet, American Outdoor Brands, Radius Health, Kaman, and FARO Technologies — What Drives Growth in Today's Competitive Landscape

    Detailed Research: Economic Perspectives on Edwards Lifesciences, Zimmer Biomet, American Outdoor Br, Feb. 06, 2019 -- In new independent research reports released early this.

  • Edwards Lifesciences Reports Fourth Quarter Results
    PR Newswire6 months ago

    Edwards Lifesciences Reports Fourth Quarter Results

    IRVINE, Calif. , Jan. 31, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...

  • Edwards Lifesciences To Host Earnings Conference Call on January 31, 2019
    PR Newswire6 months ago

    Edwards Lifesciences To Host Earnings Conference Call on January 31, 2019

    IRVINE, Calif. , Jan. 17, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...

  • PR Newswire6 months ago

    Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement

    All Patent Litigation Between the Companies to be Dismissed MARLBOROUGH, Mass. and IRVINE, Calif. , Jan. 15, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and Edwards Lifesciences Corporation ...